Form D · Biotechnology
LexaGene Holdings Inc.
Beverly, MA · CIK 0001450416
Offering snapshot reported Nov 16, 2022 · SEC filing
- Reported sold
- $1.6M Offering amount: $1.6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2022 | Initial | $1,600,000 | No comparison | 1 | SEC filing |
| Feb 28, 2022 | Amendment | $4,995,000 | $1,453,754vs Feb 17, 2022 | 1 | SEC filing |
| Feb 17, 2022 | Initial | $3,541,246 | No comparison | 1 | SEC filing |
| Feb 16, 2022 | Amendment | $3,541,246 | $2,533,389vs Oct 5, 2020 | 1 | SEC filing |
| Oct 5, 2020 | Initial | $1,007,857 | No comparison | 4 | SEC filing |
| Nov 7, 2019 | Initial | $998,828 | No comparison | 19 | SEC filing |
| Apr 15, 2019 | Initial | $115,200 | No comparison | 15 | SEC filing |
| Jul 29, 2010 | Initial | $21,375 | No comparison | 3 | SEC filing |
| Nov 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-464970
Total Offering Amount represents the principal amount of the Note. The outstanding principal of the Note is convertible into common shares at a deemed price of $0.17 on or prior to maturity on March 1, 2023.
Secured Convertible Note (the "Note") at 12% per annum interest, subject to increased interest of 16% in event of default in accordance with the terms of the Note, due March 1, 2023.
Source: Form D, filed Nov 16, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Allen V Ambrose | Director |
| Steven Armstrong | Executive |
| Mark A Campbell | Director, Executive |
| Joseph Caruso | Director |
| George Cole | Director |
| Manohar Furtado | Director |
| Krister A Kottmeier | Director, Executive |
| Stephen Mastrocola | Director |
| Jeffrey Mitchell | Executive |
| Hans Rasmussen | Director |
| Daryl Rebeck | Director, Executive |
| John (Jack) Regan | Director, Executive |
| Thomas Slezak | Director |
| Tom Slezak | Director |
| Jane Sykes | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
500 Cummings Ctr., Suite 4550
Beverly, MA, 01915
Beverly, MA, 01915